

32nd ANNUAL NORTH AMERICAN CF CONFERENCE
NACFC 2018 Abstract Categories

CATEGORY	USE THIS CATEGORY IF YOUR ABSTRACT IS ABOUT:
AIRWAYS PHYSIOLOGY, PATHOPHYSIOLOGY & AIRWAYS DEFENSE	<ul style="list-style-type: none"> • Cellular responses to infection • Endogenous antimicrobial defenses • Epithelial ion & fluid transport (including channels & regulation) • Inherent abnormalities in airway and immune cells in CF • Mechanisms of fibrosis and repair • Related therapies • Mucus secretion & clearance • Tissue function including smooth muscle and interstitium
CFTR	<ul style="list-style-type: none"> • Biogenesis & trafficking • Expression of CFTR • Pharmacology • Properties
EDUCATION	<ul style="list-style-type: none"> • Case management • CFRD • Education of healthcare professionals about CF • New complications • Newly diagnosed • Patient & family education (inpatient as well as outpatient) • Standards of care
ENDOCRINE/BONE	<ul style="list-style-type: none"> • Bone disease including (sex hormones, pregnancy hormones, growth hormones & fertility) • Diabetes
EPIDEMIOLOGY & NEWBORN SCREENING	<ul style="list-style-type: none"> • Epidemiological & newborn screening (screening studies, including newborn screening)

<p>GENETICS</p>	<ul style="list-style-type: none"> • CF-related gene expression • Counseling issues • Ethical/ legal/social issues • Genotype/phenotype relationship of diagnostic measures (including sweat testing, NPD measurement) • Heritable variations • Modifier genes
<p>GI/NUTRITION</p>	<ul style="list-style-type: none"> • Appetite stimulants • BMI, ideal body weight, macro- & micronutrients • Body composition • Energy expenditure & intake • Fatty acids & essential fatty acid profile • Feeding behavior issues • Gastrointestinal disease (including GER, DIOS, etc.) • Liver disease • Nutrition failure • Nutritional assessment & treatment • Pancreatic enzyme supplementation • Pancreatitis & pancreas-related issues • Parenteral nutrition • Tube feeding • Use of complementary/ alternative <i>supplements</i> • Vitamin/mineral supplementation
<p>INFECTION/MICROBIOLOGY</p>	<ul style="list-style-type: none"> • Antibiotics (pharmacokinetics/treatment) • Host microbe interaction • Infection control • Microbe physiology & gene expression • Microbial community profiling • Molecular epidemiology • Pathogenesis of infection • Systems biology of infection
<p>MODEL SYSTEMS</p>	<ul style="list-style-type: none"> • Animal models • Cellular models • <i>In vitro</i> systems

<p>NEW THERAPIES, BIOMARKERS & OUTCOME MEASURES</p>	<ul style="list-style-type: none"> • CFTR modulator and other pharmacological treatments • Gene therapy/editing/stem cell-based intervention • Preclinical and clinical outcome measures such as lung imaging, respiratory function, biomarkers
<p>NURSING ISSUES</p>	<ul style="list-style-type: none"> • Access to care • Advocacy • Clinic processes • Home care • Inpatient and/or outpatient nursing care • Insurance issues/third-party liaison • Nursing role on CF team • Palliative care • Patient self-management • Research coordination/management • Staff development • Team coordination • Telephone management/triage • The role of advanced practice nurses- (including management issues and clinical care) • Transition programs • Venous access devices
<p>PHYSICAL & RESPIRATORY THERAPY</p>	<ul style="list-style-type: none"> • Airway clearance techniques • Exercise • Musculoskeletal & neuromuscular problems/therapies • Urinary & bowel incontinence

PSYCHOSOCIAL/BEHAVIORAL	<ul style="list-style-type: none"> • Adaptation of patients & families to diagnosis & medical interventions • Adherence • Complementary/alternative therapies (except supplements) assessment • Emotional/social/behavioral/ sexual development • End-of-life issues • Family functioning, parenting & marital issues • Life expectations • Measurement & use of quality of life tools • Pain management • Patient/family/caregiver interaction & communication • Problems of dealing with chronic disease • Psychosocial impact of transition to adult care • Support system development • Treatment of psychological/psychiatric disorders (including depression, anxiety, etc.)
PULMONARY	<ul style="list-style-type: none"> • Aerosol delivery systems (including new ones) • Evaluation (including PFTs, BAL, bronchoscopy, radiological assessment, etc.) • Pathology • Pulmonary exacerbations/ treatment • Pulmonary physiology
QUALITY IMPROVEMENT	<ul style="list-style-type: none"> • QI (including projects/efforts/tools & patient & family involvement)
TRANSPLANTATION	<ul style="list-style-type: none"> • Medical, psychosocial & epidemiological issues related to organ transplantation in CF
UTILIZATION AND COVERAGE	<ul style="list-style-type: none"> • Access to care • Advocacy • Case management • Cost & payment • Cost effectiveness analysis • Health and healthcare disparities • Health care utilization • Insurance issues/ third-party liaison